These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 30354361

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effect of Iron Isomaltoside on Skeletal Muscle Energetics in Patients With Chronic Heart Failure and Iron Deficiency.
    Charles-Edwards G, Amaral N, Sleigh A, Ayis S, Catibog N, McDonagh T, Monaghan M, Amin-Youssef G, Kemp GJ, Shah AM, Okonko DO.
    Circulation; 2019 May 21; 139(21):2386-2398. PubMed ID: 30776909
    [Abstract] [Full Text] [Related]

  • 3. Intravenous iron supplementation improves energy metabolism of exercising skeletal muscles without effect on either oxidative stress or inflammation in male patients with heart failure with reduced ejection fraction.
    Drozd MD, Tkaczyszyn M, Kasztura M, Węgrzynowska-Teodorczyk K, Flinta I, Banasiak W, Ponikowski P, Jankowska EA.
    Cardiol J; 2024 May 21; 31(2):300-308. PubMed ID: 37853824
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency.
    van Veldhuisen DJ, Ponikowski P, van der Meer P, Metra M, Böhm M, Doletsky A, Voors AA, Macdougall IC, Anker SD, Roubert B, Zakin L, Cohen-Solal A, EFFECT-HF Investigators.
    Circulation; 2017 Oct 10; 136(15):1374-1383. PubMed ID: 28701470
    [Abstract] [Full Text] [Related]

  • 6. Comparisons of the skeletal muscle metabolic abnormalities in the arm and leg muscles of patients with chronic heart failure.
    Nagai T, Okita K, Yonezawa K, Yamada Y, Hanada A, Ohtsubo M, Morita N, Murakami T, Nishijima H, Kitabatake A.
    Circ J; 2004 Jun 10; 68(6):573-9. PubMed ID: 15170095
    [Abstract] [Full Text] [Related]

  • 7. Contribution of skeletal muscle atrophy to exercise intolerance and altered muscle metabolism in heart failure.
    Mancini DM, Walter G, Reichek N, Lenkinski R, McCully KK, Mullen JL, Wilson JR.
    Circulation; 1992 Apr 10; 85(4):1364-73. PubMed ID: 1555280
    [Abstract] [Full Text] [Related]

  • 8. Contribution of specific skeletal muscle metabolic abnormalities to limitation of exercise capacity in patients with chronic heart failure: a phosphorus 31 nuclear magnetic resonance study.
    Chati Z, Zannad F, Robin-Lherbier B, Escanye JM, Jeandel C, Robert J, Aliot E.
    Am Heart J; 1994 Oct 10; 128(4):781-92. PubMed ID: 7942449
    [Abstract] [Full Text] [Related]

  • 9. A non-invasive selective assessment of type I fibre mitochondrial function using 31P NMR spectroscopy. Evidence for impaired oxidative phosphorylation rate in skeletal muscle in patients with chronic heart failure.
    van der Ent M, Jeneson JA, Remme WJ, Berger R, Ciampricotti R, Visser F.
    Eur Heart J; 1998 Jan 10; 19(1):124-31. PubMed ID: 9503185
    [Abstract] [Full Text] [Related]

  • 10. Physical deconditioning may be a mechanism for the skeletal muscle energy phosphate metabolism abnormalities in chronic heart failure.
    Chati Z, Zannad F, Jeandel C, Lherbier B, Escanye J-M, Robert J, Aliot E.
    Am Heart J; 1996 Mar 10; 131(3):560-6. PubMed ID: 8604638
    [Abstract] [Full Text] [Related]

  • 11. Effects of oral supplementation of coenzyme Q10 on 31P-NMR detected skeletal muscle energy metabolism in middle-aged post-polio subjects and normal volunteers.
    Mizuno M, Quistorff B, Theorell H, Theorell M, Chance B.
    Mol Aspects Med; 1997 Mar 10; 18 Suppl():S291-8. PubMed ID: 9266539
    [Abstract] [Full Text] [Related]

  • 12. Skeletal muscle function and its relation to exercise tolerance in chronic heart failure.
    Harrington D, Anker SD, Chua TP, Webb-Peploe KM, Ponikowski PP, Poole-Wilson PA, Coats AJ.
    J Am Coll Cardiol; 1997 Dec 10; 30(7):1758-64. PubMed ID: 9385904
    [Abstract] [Full Text] [Related]

  • 13. Iron-regulatory proteins secure iron availability in cardiomyocytes to prevent heart failure.
    Haddad S, Wang Y, Galy B, Korf-Klingebiel M, Hirsch V, Baru AM, Rostami F, Reboll MR, Heineke J, Flögel U, Groos S, Renner A, Toischer K, Zimmermann F, Engeli S, Jordan J, Bauersachs J, Hentze MW, Wollert KC, Kempf T.
    Eur Heart J; 2017 Feb 01; 38(5):362-372. PubMed ID: 27545647
    [Abstract] [Full Text] [Related]

  • 14. Metabolic abnormality of calf skeletal muscle is improved by localised muscle training without changes in blood flow in chronic heart failure.
    Ohtsubo M, Yonezawa K, Nishijima H, Okita K, Hanada A, Kohya T, Murakami T, Kitabatake A.
    Heart; 1997 Nov 01; 78(5):437-43. PubMed ID: 9415000
    [Abstract] [Full Text] [Related]

  • 15. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
    Schatz U, Illigens BM, Siepmann T, Arneth B, Siegert G, Siegels D, Heigl F, Hettich R, Ramlow W, Prophet H, Bornstein SR, Julius U.
    Atheroscler Suppl; 2015 May 01; 18():199-208. PubMed ID: 25936327
    [Abstract] [Full Text] [Related]

  • 16. Phosphorus 31 nuclear magnetic resonance spectroscopy suggests a mitochondrial defect in claudicating skeletal muscle.
    Pipinos II, Shepard AD, Anagnostopoulos PV, Katsamouris A, Boska MD.
    J Vasc Surg; 2000 May 01; 31(5):944-52. PubMed ID: 10805885
    [Abstract] [Full Text] [Related]

  • 17. Heart failure in patients with kidney disease and iron deficiency; the role of iron therapy.
    Cases Amenós A, Ojeda López R, Portolés Pérez JM, en representación del Grupo de Anemia de la S.E.N..
    Nefrologia; 2017 May 01; 37(6):587-591. PubMed ID: 28610806
    [Abstract] [Full Text] [Related]

  • 18. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis.
    Anker SD, Kirwan BA, van Veldhuisen DJ, Filippatos G, Comin-Colet J, Ruschitzka F, Lüscher TF, Arutyunov GP, Motro M, Mori C, Roubert B, Pocock SJ, Ponikowski P.
    Eur J Heart Fail; 2018 Jan 01; 20(1):125-133. PubMed ID: 28436136
    [Abstract] [Full Text] [Related]

  • 19. Bio-energetic impairment in human calf muscle in thyroid disorders: a 31P MRS study.
    Khushu S, Rana P, Sekhri T, Sripathy G, Tripathi RP.
    Magn Reson Imaging; 2010 Jun 01; 28(5):683-9. PubMed ID: 20332062
    [Abstract] [Full Text] [Related]

  • 20. The effect of intravenous ferric carboxymaltose on red cell distribution width: a subanalysis of the FAIR-HF study.
    Van Craenenbroeck EM, Conraads VM, Greenlaw N, Gaudesius G, Mori C, Ponikowski P, Anker SD.
    Eur J Heart Fail; 2013 Jul 01; 15(7):756-62. PubMed ID: 23639779
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.